Safety and Efficacy of IL-12 Plasmid DNA Transfection into Pig Skin: Supportive Data for Human Clinical Trials on Gene Therapy and Vaccination
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25063151 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ursa Lampreht Tratar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Interleukin-12, Gene Transfer Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research Agency, Slovenian Research and Innovation Agency (ARIS).
Abstract (Originalsprache)
Gene electrotransfer (GET) of plasmids encoding interleukin 12 (IL-12) has already been used for the treatment of various types of tumors in human oncology and as an adjuvant in DNA vaccines. In recent years, we have developed a plasmid encoding human IL-12 (phIL12) that is currently in a phase I clinical study. The aim was to confirm the results of a non-clinical study in mice on pharmacokinetic characteristics and safety in a porcine model that better resembled human skin. The GET of phIL12 in the skin was performed on nine pigs using different concentrations of plasmid phIL12 and invasive (needle) or noninvasive (plate) types of electrodes. The results of our study demonstrate that the GET of phIL-12 with needle electrodes induced the highest expression of IL-12 at the protein level on day 7 after the procedure. The plasmid was distributed to all tested organs; however, its amount decreased over time and was at a minimum 28 days after GET. Based on plasmid copy number and expression results, together with blood analysis, we showed that IL-12 GET is safe in a porcine animal model. Furthermore, we demonstrated that pigs are a valuable model for human gene therapy safety studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
- Small Animal Clinic, Veterinary Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, Askerčeva 7, 1000 Ljubljana, Slovenia.
- Department of Abdominal Surgery, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
- Faculty of Health Sciences, University of Ljubljana, 1000 Ljubljana, Slovenia.
ORCID-Profile: Ursa Lampreht Tratar, Tanja Jesenko, Alenka Seliskar, Gregor Sersa, Maja Cemazar
Förderung
- Slovenian Research Agency
- Slovenian Research and Innovation Agency (ARIS)
Zitieren
APA
Lampreht Tratar, U., Jesenko, T., Omerzel, M., Seliskar, A., Stupan, U., Djokic, M., Sredensek, J., Trotovsek, B., Sersa, G., & Cemazar, M. (2024). Safety and Efficacy of IL-12 Plasmid DNA Transfection into Pig Skin: Supportive Data for Human Clinical Trials on Gene Therapy and Vaccination. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063151
Vancouver
Lampreht Tratar U, Jesenko T, Omerzel M, Seliskar A, Stupan U, Djokic M, et al. Safety and Efficacy of IL-12 Plasmid DNA Transfection into Pig Skin: Supportive Data for Human Clinical Trials on Gene Therapy and Vaccination. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063151
BibTeX
@article{LamprehtTratar2024,
author = {Lampreht Tratar, Ursa and Jesenko, Tanja and Omerzel, Masa and Seliskar, Alenka and Stupan, Urban and Djokic, Mihajlo and Sredensek, Jerneja and Trotovsek, Blaz and Sersa, Gregor and Cemazar, Maja},
title = {Safety and Efficacy of IL-12 Plasmid DNA Transfection into Pig Skin: Supportive Data for Human Clinical Trials on Gene Therapy and Vaccination},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25063151}
}
EUVIMED